| Complication | Evidence | PMID |
| Nephropathy | 1. Pro12Ala polymorphism of the PPARG gene may be associated with diabetic nephropathy among Asians. 2. Our results support an important association between rs1805192 minor allele (G allele) of PPARG and increased DN risk; the interaction analysis showed a combined effect of G allele?WC interaction between rs1805192 and abdominal obesity on DN risk. The possible synergistic effects between the genotype and abdominal obesity implied that a positive interaction between genetic and nongenetic factors may contribute to the development of DN in Chinese type 2 diabetic patients. | 22103651 |
| Retinopathy | 1. Therapeutic targeting of PPARgamma may be beneficial to diabetic retinopathy. 2. Suppression of PPARgamma is involved in the pathogenesis of diabetic retinopathy and OIR. 3. We therefore hypothesized that the Gly482Ser polymorphism of the PPARGC1 gene and Pro12Ala polymorphism of the PPARgamma gene might confer susceptibility to diabetic retinopathy in type 2 diabetes. 4. Suppression of PPARgamma is involved in the pathogenesis of diabetic retinopathy and Oxygen-induced retinopathy OIR. DPH oxidase could be an upstream mediator of these changes. | 18309374 |
| Atherosclerosis | 1. Thus in addition to the treatment of type II diabetes, PPARgamma agonists can be potentially employed for the treatment of atherosclerosis in general population 2. These findings suggest that PPARgamma activators, currently used in treatment of type II diabetes, may have beneficial effects in modulating inflammatory response in atherosclerosis. " | 12682906 |
| Dyslipidemia | 1. A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia. | 20123124 |
| Insulin resistance and inflammation | 1. Knockdown of PPARG downregulated SCAMP3 expression at the late phase of adipogenesis, whereas reduction of SCAMP3 mRNA levels increased PPARG expression at early phase in differentiation. | 31554889 |
